Utama › Karsinoma Sel Skuamosa Kepala dan Leher › Florida › Orlando
Kajian klinikal Karsinoma Sel Skuamosa Kepala dan Leher di Orlando, FL
16 kajian untuk Karsinoma Sel Skuamosa Kepala dan Leher sedang mencari peserta di lokasi dalam dan sekitar Orlando (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.
Teks kajian rasmi (Bahasa Inggeris)
Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
Mengambil pesertaFasa 1
- Exelixis Clinical Site #48, Celebration · 17 mi jauh
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
Mengambil pesertaFasa 3
- AdventHealth Medical Group Oncology and Hematology at Orlando, Orlando
JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC
Mengambil pesertaFasa 3
- AdventHealth Orlando, Orlando
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
Mengambil pesertaFasa 1
- Sara Cannon Research Institute Lake Nona, Orlando
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
Mengambil pesertaFasa 1/2
- Florida Cancer Specialists - Lake Nona, Orlando
A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Mengambil pesertaFasa 2
- Orlando Health, Orlando
SMP-3124LP in Adults With Advanced Solid Tumors
Mengambil pesertaFasa 1/2
- Advent Health, Celebration · 17 mi jauh
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Mengambil pesertaFasa 1/2
- Clermont Oncology Center, Clermont · 24 mi jauh
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
Mengambil pesertaFasa 1/2
- Sarah Cannon Research Institute (Lake Nona), Orlando
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
Mengambil pesertaFasa 1
- Florida Cancer Specialists - Lake Nona, Orlando
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Mengambil pesertaFasa 1
- Florida Cancer Specialists, Orlando
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
Mengambil pesertaFasa 3
- AdventHealth Medical Group Oncology & Hematology at Orlando, Orlando
A Study of DB-1310 in Advanced/Metastatic Solid Tumors
Mengambil pesertaFasa 1/2
- Sarah Cannon Research Institute at Florida Cancer Specialists, Orlando
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
Mengambil pesertaFasa 1/2
- Florida Cancer Specialists-Lake Nona, Orlando
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
Mengambil pesertaFasa 1
- Dren Investigational Site, Orlando
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
Mengambil pesertaFasa 1/2
- Research Site 137, Orlando
- Research Site 118, Celebration · 17 mi jauh
Kajian Karsinoma Sel Skuamosa Kepala dan Leher di bandar lain
- Houston, TX47 kajian
- Los Angeles, CA42 kajian
- Boston, MA40 kajian
- New York City, NY39 kajian
- Nashville, TN39 kajian
- St. Louis, MO28 kajian
- Arlington, VA26 kajian
- Philadelphia, PA26 kajian
- Chicago, IL26 kajian
- Atlanta, GA24 kajian
- San Antonio, TX22 kajian
- New Haven, CT22 kajian
Kajian lain di Orlando
- Kanser Paru-paru Bukan Sel Kecil44 kajian
- Obesiti32 kajian
- Kanser Metastatik29 kajian
- Berat Badan Berlebihan27 kajian
- Penyakit Alzheimer25 kajian
- Diabetes Jenis 225 kajian
- Kanser (semua jenis)24 kajian
- Kanser Payudara23 kajian
- Kanser Ovari22 kajian
- Kolitis Ulseratif22 kajian
- Kanser Paru-paru21 kajian
- Kanser Kolorektal19 kajian
Daripada ClinicalTrials.gov, data diperoleh pada 6 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.